GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
Series GSE53084 Query DataSets for GSE53084
Status Public on Aug 18, 2014
Title Cross-platform toxicogenomics for the prediction of nongenotoxic hepatocarcinogenesis in rat (protein)
Platform organism Mus musculus
Sample organism Rattus norvegicus
Experiment type Protein profiling by protein array
Summary In this study we performed microarray-based molecular profiling of liver samples from Wistar rats exposed to genotoxic carcinogens (GC), nongenotoxic carcinogens (NGC) or non-hepatocarcinogens (NC) for up to 14 days. In contrast to previous toxicogenomics studies aimed at the inference of molecular signatures for assessing the potential and mode of compound carcinogenicity, we considered multi-level omics data. Besides evaluating the predictive power of signatures observed on individual biological levels, such as mRNA, miRNA and protein expression, we also introduced novel feature representations which capture putative molecular interactions or pathway alterations by integrating expression profiles across platforms interrogating different biological levels.
Overall design Male Wistar rats were treated by oral gavage with the eight nongenotoxic hepatocarcinogens Phenobarbital sodium (PB), Piperonylbutoxide (PBO), Dehydroepiandrosterone (DHEA), Acetamide (AA), Methapyrilene HCl (MPy), Methylcarbamate (Mcarb), Diethylstilbestrol (DES) and Ethionine (ETH), the two genotoxic carcinogens C.I Direct Black (CIDB) and dimethylnitrosamine (DMN), the two non-hepatocarcinogens Cefuroxime (CFX) and Nifedipine (Nif), and the three compounds with undefined carcinogenic class Cyproterone acetate (CPA), Thioacetamid (TAA) and Wy-14643 (Wy). Depending on the administered compound, livers were taken after 3, 7, or 14 days for histopathological evaluation. From the five animals per treatment group three animals were selected based on the histopathological findings and subjected to molecular profiling using Affymetrix RG-230A arrays (mRNA expression), Agilent G4473A arrays (miRNA expression) and Zeptosens ZeptoMARK reverse arrays (protein expression).
Contributor(s) Römer M, Ellinger-Ziegelbauer H, Eichner J
Citation(s) 24830643, 26882475
Submission date Dec 06, 2013
Last update date Oct 04, 2019
Contact name Jonathan Moggs
Organization name Novartis
Street address Fabrikstrasse 2
City Basel
ZIP/Postal code 4056
Country Switzerland
Platforms (1)
GPL17787 ZeptoMARK assay platform
Samples (63)
GSM1282018 AA_rep1
GSM1282019 AA_rep2
GSM1282020 AA_rep3
This SubSeries is part of SuperSeries:
GSE53085 Cross-platform toxicogenomics for the prediction of nongenotoxic hepatocarcinogenesis in rat
GSE68387 IMI MARCAR Project: towards novel biomarkers for cancer risk assessment
BioProject PRJNA230816

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE53084_RAW.tar 190.0 Kb (http)(custom) TAR (of CSV)
Processed data included within Sample table

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap